197 related articles for article (PubMed ID: 32827151)
1. SGLT2 Inhibitors and Bladder Cancer: Analysis of Cases Reported in the European Pharmacovigilance Database.
García M; Arteche-Martinez U; Lertxundi U; Aguirre C
J Clin Pharmacol; 2021 Feb; 61(2):187-192. PubMed ID: 32827151
[TBL] [Abstract][Full Text] [Related]
2. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
[TBL] [Abstract][Full Text] [Related]
3. Do sodium-glucose cotransporter 2 inhibitors lead to fracture risk? A pharmacovigilance real-world study.
Zhao B; Shen J; Zhao J; Pan H
J Diabetes Investig; 2021 Aug; 12(8):1400-1407. PubMed ID: 33325646
[TBL] [Abstract][Full Text] [Related]
4. Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis.
Menne J; Dumann E; Haller H; Schmidt BMW
PLoS Med; 2019 Dec; 16(12):e1002983. PubMed ID: 31815931
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add-on to metformin in type 2 diabetes.
Zhou Y; Geng Z; Wang X; Huang Y; Shen L; Wang Y
Diabetes Metab Res Rev; 2020 Feb; 36(2):e3223. PubMed ID: 31642583
[TBL] [Abstract][Full Text] [Related]
6. Sodium-glucose cotransporter-2 inhibitors and cardiovascular safety profile: a pharmacovigilance analysis of the US food and drug administration adverse event reporting system.
Zhang L; Pan C; Yang X; Jiang D; Cao M
Expert Opin Drug Saf; 2024 Jun; 23(6):785-792. PubMed ID: 37203199
[TBL] [Abstract][Full Text] [Related]
7. Tramadol-induced hiccups: a case-noncase study in the European pharmacovigilance database.
García M; Lertxundi U; Aguirre C
Ther Adv Drug Saf; 2021; 12():20420986211021230. PubMed ID: 34211690
[TBL] [Abstract][Full Text] [Related]
8. Acute kidney injury following SGLT2 inhibitors among diabetic patients: a pharmacovigilance study.
Chen G; Li X; Cui Q; Zhou Y; Zhao B; Mei D; Xuemei
Int Urol Nephrol; 2022 Nov; 54(11):2949-2957. PubMed ID: 35579781
[TBL] [Abstract][Full Text] [Related]
9. Clinical Adverse Events Associated with Sodium-Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71 553 Individuals.
Lin DS; Lee JK; Chen WJ
J Clin Endocrinol Metab; 2021 Jun; 106(7):2133-2145. PubMed ID: 33895840
[TBL] [Abstract][Full Text] [Related]
10. Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System.
Hu Y; Bai Z; Tang Y; Liu R; Zhao B; Gong J; Mei D
J Diabetes Res; 2020; 2020():3695101. PubMed ID: 32695827
[TBL] [Abstract][Full Text] [Related]
11. Adherence, Persistence, and Switching Among People Prescribed Sodium Glucose Co-transporter 2 Inhibitors: A Nationwide Retrospective Cohort Study.
Ofori-Asenso R; Liew D; Lalic S; Mazidi M; Magliano DJ; Ademi Z; Bell JS; Ilomaki J
Adv Ther; 2019 Nov; 36(11):3265-3278. PubMed ID: 31482509
[TBL] [Abstract][Full Text] [Related]
12. SGLT-2 inhibitors and ketoacidosis: a disproportionality analysis in the World Health Organization's adverse drug reactions database.
Ado Moumouni AN; Robin P; Hillaire-Buys D; Faillie JL
Fundam Clin Pharmacol; 2018 Apr; 32(2):216-226. PubMed ID: 29144574
[TBL] [Abstract][Full Text] [Related]
13. Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
Euh W; Lim S; Kim JW
Front Endocrinol (Lausanne); 2021; 12():613389. PubMed ID: 34177796
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide-1 analogues and thyroid cancer: An analysis of cases reported in the European pharmacovigilance database.
Mali G; Ahuja V; Dubey K
J Clin Pharm Ther; 2021 Feb; 46(1):99-105. PubMed ID: 32926446
[TBL] [Abstract][Full Text] [Related]
15. The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study.
Goldman A; Fishman B; Twig G; Raschi E; Cukierman-Yaffe T; Moshkovits Y; Pomerantz A; Ben-Zvi I; Dankner R; Maor E
Cardiovasc Diabetol; 2023 Jan; 22(1):16. PubMed ID: 36694178
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the risk of SGLT2is and NonSGLT2is in leading to amputation: A network meta-analysis.
Qiu M; Ding LL; Zhang M; Zhou HR
J Diabetes Complications; 2021 Feb; 35(2):107803. PubMed ID: 33293207
[TBL] [Abstract][Full Text] [Related]
17. Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database.
Perlman A; Heyman SN; Matok I; Stokar J; Muszkat M; Szalat A
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1108-1113. PubMed ID: 29174031
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Serum Electrolyte Levels in Patients with Type 2 Diabetes: A Pairwise and Network Meta-Analysis of Randomized Controlled Trials.
Zhang J; Huan Y; Leibensperger M; Seo B; Song Y
Kidney360; 2022 Mar; 3(3):477-487. PubMed ID: 35582188
[TBL] [Abstract][Full Text] [Related]
19. An update on the safety of SGLT2 inhibitors.
Scheen AJ
Expert Opin Drug Saf; 2019 Apr; 18(4):295-311. PubMed ID: 30933547
[TBL] [Abstract][Full Text] [Related]
20. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature.
Bonora BM; Avogaro A; Fadini GP
Diabetes Obes Metab; 2018 Jan; 20(1):25-33. PubMed ID: 28517913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
